Steady state

Steady state is the pharmacokinetic condition reached during repeated dosing when the rate at which a drug enters the body exactly equals the rate at which the body clears it. Rather than climbing with each successive dose, plasma concentrations settle into a stable rhythm — oscillating between a post-dose peak and a pre-dose trough, but averaging to a constant level over time.

The timeline to reach steady state is governed by the substance's half-life — the time required for the body to eliminate half the drug in circulation. Regardless of how large each dose is, equilibrium arrives after roughly four to five half-lives. A substance with a two-hour half-life reaches steady state in about a day; one with a two-day half-life takes close to two weeks.

How it works · its role

Before steady state, each new dose arrives while measurable drug from the previous dose is still in circulation, so concentrations accumulate over successive administrations. The body's clearance mechanisms — primarily liver metabolism and renal excretion — are active throughout, but their combined output initially lags behind intake. As concentrations rise, clearance keeps pace, because more drug in circulation drives faster elimination. When the two rates equalise, accumulation stops.

Dose size sets where the plateau sits; half-life sets how long it takes to arrive. A higher dose or shorter dosing interval raises the average concentration at plateau and compresses the swing between peak and trough, but neither shortens the timeline to equilibrium. This is the rationale behind loading doses: a larger initial dose that pushes concentrations toward the target plateau immediately, bypassing the accumulation phase entirely.

Relevance to substances & effects

Steady state is central to understanding how many substances feel — and how their effects evolve — over days or weeks of regular use. SSRIs and SNRIs are taken daily for several weeks before plasma concentrations stabilise, which partly accounts for their delayed onset of effect. Stopping them abruptly causes concentrations to drop away from the established plateau, producing the discontinuation symptoms associated with these drug classes.

Substances with long half-lives, such as methadone and diazepam, reach steady state slowly but maintain relatively stable concentrations between doses, with smaller swings between peak and trough. Shorter-acting drugs produce sharper oscillations, which often translate to more pronounced cycling of subjective effects through the dosing day.

For substances used outside clinical settings, steady-state dynamics shape how quickly tolerance develops, how long a substance remains detectable after the last dose, and how effects during the first days of a new dosing pattern may differ from those once equilibrium is reached.